Response to imatinib mesylate therapy by CML phase
| . | Chronic . | Clonal evolution . | Accelerated, no clonal evolution . | Accelerated + clonal evolution . |
|---|---|---|---|---|
| Total/active disease | 295/179 | 70/45 | 82 | 51 |
| CHR, n (%) | 163 (91) | 39 (87) | 67 (82) | 37 (73) |
| Cytogenetic response, n (%) | 209 (71) | 42 (60) | 41 (50) | 21 (41) |
| Complete | 158 (54) | 31 (44) | 28 (34) | 13 (25) |
| Partial | 35 (12) | 7 (10) | 5 (6) | 4 (8) |
| Minor | 16 (5) | 4 (6) | 8 (10) | 4 (8) |
| Partial hematologic response | 5 | 3 | 8 | 4 |
| Resistant + inevaluable | 7 + 4 | 1 + 2 | 3 + 4 | 9 + 1 |
| . | Chronic . | Clonal evolution . | Accelerated, no clonal evolution . | Accelerated + clonal evolution . |
|---|---|---|---|---|
| Total/active disease | 295/179 | 70/45 | 82 | 51 |
| CHR, n (%) | 163 (91) | 39 (87) | 67 (82) | 37 (73) |
| Cytogenetic response, n (%) | 209 (71) | 42 (60) | 41 (50) | 21 (41) |
| Complete | 158 (54) | 31 (44) | 28 (34) | 13 (25) |
| Partial | 35 (12) | 7 (10) | 5 (6) | 4 (8) |
| Minor | 16 (5) | 4 (6) | 8 (10) | 4 (8) |
| Partial hematologic response | 5 | 3 | 8 | 4 |
| Resistant + inevaluable | 7 + 4 | 1 + 2 | 3 + 4 | 9 + 1 |